CI-581b

DRUG5 trials

Sponsors

New York State Psychiatric Institute

Conditions

Alcohol DependenceAlcohol Use DisorderCocaine DependenceCocaine Use DisorderCognitive DysfunctionDepressive SymptomsPost-acute Sequelae of COVID-19

Phase 2

Glutamatergic Modulation of Disordered Alcohol Use

CompletedNCT02539511

New York State Psychiatric InstituteAlcohol Dependence

Start: 2015-07-31End: 2017-12-31Updated: 2020-02-11

The Effect of Glutamatergic Modulation on Cocaine Self-administration

CompletedNCT02596022

New York State Psychiatric InstituteCocaine Dependence

Start: 2013-06-30End: 2015-07-31Updated: 2018-06-15

The Role of Brief Potent Glutamatergic Modulation in Addressing Problem Drinking

New York State Psychiatric InstituteAlcohol Use Disorder

Start: 2019-11-08End: 2024-08-31Target: 120Updated: 2023-11-07

Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial

Active, not recruitingNCT05690503

New York State Psychiatric InstituteCognitive Dysfunction, Depressive Symptoms, Post-acute Sequelae of COVID-19

Start: 2023-03-20End: 2025-12-31Target: 12Updated: 2024-07-16

Phase 3

Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders

SuspendedNCT03344419

New York State Psychiatric InstituteCocaine Use Disorder

Start: 2017-10-01End: 2024-12-31Target: 150Updated: 2024-07-16